Application of thermophilic radiation-resistant sinococcus in tumor immunotherapy

By combining thermophilic radiation-resistant Miagra and immune checkpoint inhibitors, killer T cell activation in the tumor microenvironment is enhanced, and the problem of low remission rate of tumor immunotherapy is solved, and the effect of tumor immunotherapy is significantly improved.

CN119015324APending Publication Date: 2024-11-26BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310606110.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The response rate of tumor immunotherapy is low, especially tumors such as lung squamous cell carcinoma, which is mainly due to immune escape and immunosuppression, which is unable to effectively recognize and attack tumor cells.

Method used

Deinococcus geothermalis is used to bind to immune checkpoint inhibitors (such as PD-1 inhibitors) to enhance killer T cell activation in the tumor microenvironment and promote anti-tumor immune response.

Benefits of technology

It significantly increases the activation of killer T cells in the tumor microenvironment and the secretion of TNF-α and IFN-γ, effectively inhibits tumor growth and improves the efficacy of tumor immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004250615510000011
    Figure HDA0004250615510000011
  • Figure HDA0004250615510000012
    Figure HDA0004250615510000012
  • Figure HDA0004250615510000013
    Figure HDA0004250615510000013
Patent Text Reader

Abstract

The invention provides an application of thermophilic radiation-resistant sinococcus in tumor immunotherapy. Specifically, the invention provides a pharmaceutical composition or a kit, and the pharmaceutical composition or the kit comprises the thermophilic deinococcus radiodurans (Deinococcus radiodurans) and an immune checkpoint inhibitor. The thermophilic radiation-resistant sinococcus is combined with the immune checkpoint inhibitor, so that the anti-tumor effect can be realized by increasing the activity of killer T cells in a tumor microenvironment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the application of thermophilic Deinococcus geothermalis, and in particular to the application of thermophilic Deinococcus geothermalis in enhancing tumor immunotherapy. Background Art

[0002] Trillions of microorganisms that coexist with the human body participate in the body's immune, metabolic, and hormone regulation processes, and have also been shown to be involved in the occurrence and development of a variety of diseases, including tumors. Studies have shown that regulating the microbiome in germ-free mice can enhance anti-tumor immunity and enhance the effect of blocking immune checkpoints. Recently, using cell culture and animal models, human preclinical studies and clinical studies have shown that symbiotic microbiota has a profound effect on the host immune system and is considered to be one of the factors affecting anti-tumor immunity and therapeutic effects. Therefore, the tumor polymorphic microbiomes have attracted extensive research and were added to one of the four new "attributed characteristics" of tumors by Professor Douglas Hanahan in early 2022 (Hanahan, D., Hallmarks of Cancer: New Dimensions. Cancer Discov, 2022.12(1): p.31-46).

[0003] Immunotherapy is a method of treating cancer that has developed rapidly in recent years. It controls or cures tumors by activating or enhancing the anti-tumor response of the body's immune system. Although immunotherapy has shown certain potential in tumor treatment, the response rate of immunotherapy is still relatively low for some tumors. For example, squamous cell carcinoma of the lung, pancreatic cancer, and gastric cancer, the response rate of immunotherapy is about 10%. The main reason is that this type of tumor has the characteristics of immune escape and immunosuppression, which makes the patient's immune system unable to effectively identify and attack tumor cells. In addition, squamous cell carcinoma of the lung has fewer genetic mutations, resulting in low antigen expression levels in tumor cells, which also limits the effect of immunotherapy. In recent years, more and more studies have shown that there is a close relationship between the intestinal microbiota and the immune system, and changes in the intestinal microbiota may affect the function of the immune system. Therefore, the use of microbial preparations to regulate the immune system to improve the efficacy of tumor immunotherapy has become an emerging research field that has attracted much attention.

[0004] Currently, clinical efforts to improve the efficacy of tumor immunotherapy are mainly based on the use of microbial preparations with immune-stimulating properties. Among them, microbiota transplantation is a method that has been proven to regulate the intestinal microbiota. It improves the patient's immune system function by transplanting the intestinal microbiota of healthy people into the patient's intestine. Some studies have shown that microbiota transplantation can improve the efficacy of tumor immunotherapy, but its specific mechanism still needs further study.

[0005] In addition, microbial preparations such as defined probiotic strains, synbiotics or postbiotics are also considered to have potential immunomodulatory effects and can be used as adjuvant therapy to improve the efficacy of tumor immunotherapy. However, research on these microbial preparations is still in its infancy, and more clinical trials are needed to confirm their effectiveness and safety.

[0006] Deinococcus geothermalis (D.geothermalis) is a Gram-positive bacterium, but its cell membrane structure is multilayered and its lipid composition is similar to that of Gram-negative bacteria: its cell membrane consists of at least five layers (cytoplasmic membrane, peptidoglycan layer, septal layer, inner layer and crystalline surface layer (S layer)). The peptidoglycan layer is composed of mucopeptides, which contain glucosamine, muramic acid and four major amino acids (glutamic acid, alanine, glycine and L-ornithine). The S layer contains carotenoids, lipid proteins and polysaccharides. Its main feature is that it can tolerate DNA damage caused by ionizing radiation and ultraviolet radiation, and grow at temperatures up to 55 degrees Celsius and in the presence of long-term radiation (50Gy / hour). It is known as the "world's most tenacious bacteria". Its main function is to reduce Hg(II) in the presence of radiation and high temperature; in addition, D.geothermalis can reduce Fe(III)-NTA, U(VI) and Cr(VI). These properties support the prospective development of this thermophilic radioactive material for bioremediation of radioactive mixed waste environments with temperatures as high as 55 degrees Celsius. D.geothermalis is extremely resistant to a variety of DNA damage caused by ionizing radiation or ultraviolet (UV) radiation. Mechanistic studies have found that D.geothermalis can accurately and efficiently repair more than 100 DNA double-strand breaks (DSBs) caused by radiation in cells. At present, studies have found that the Deinococcaceae family to which D.geothermalis bacteria belong are all non-pathogenic and radiation-resistant bacteria. Although it has been reported that Deinococcaceae can be used to treat and / or prevent lung conditions, the specific strain D.geothermalis was first isolated from hot springs with higher temperatures and its high temperature and radiation resistance characteristics, so the current research and application of D.geothermalis is limited to environmental modification and bioremediation, and no studies have reported the relationship between D.geothermalis strains and human diseases. Summary of the invention

[0007] A technical problem to be solved by the present invention is to provide a method and composition for fighting tumors and promoting the efficacy of tumor immunotherapy, in view of the current difficulties in tumor immunotherapy, especially the problem of low remission rate of tumor immunotherapy.

[0008] The inventors of this case found in their research that thermophilic radioresistant Deinococcus geothermalis (D.geothermalis) has the effect of promoting the efficacy of immunotherapy. Functional experimental results showed that D.geothermalis not only promoted T cells to secrete IFN-γ and TNF-α, but also affected the PD-1 inhibitor-mediated killing effect of cytotoxic T cells on tumors such as squamous cell lung cancer organoids, suggesting that D.geothermalis has a certain significance for immunotherapy and is expected to be applied in tumor immunotherapy drug response diagnosis and prognosis evaluation such as squamous cell lung cancer.

[0009] Thus, the present invention provides the use of thermophilic radioresistant Deinococcus geothermalis in combination with immune checkpoint inhibitors for anti-tumor immunotherapy.

[0010] Specifically, on the one hand, the present invention provides the use of thermophilic radioresistant Deinococcus geormali combined with immune checkpoint inhibitors in the preparation of a composition for enhancing tumor immunotherapy.

[0011] According to a specific embodiment of the present invention, the thermophilic radioresistant Deinococcus of the present invention is used in the preparation of a composition for enhancing tumor immunotherapy to increase the infiltration of cytotoxic T cells in the tumor microenvironment and thus fight tumors.

[0012] According to a specific embodiment of the present invention, the thermophilic radioresistant Deinococcus described in the present invention is any one of the following: live thermophilic radioresistant Deinococcus; a lysate or culture of thermophilic radioresistant Deinococcus; or, attenuated, inactivated, physically treated or chemically treated thermophilic radioresistant Deinococcus, or a lysate or culture thereof.

[0013] The tumor described in the present invention can be various solid tumors, such as but not limited to lung cancer, esophageal cancer, gastric cancer, colorectal cancer, melanoma, liver cancer, breast cancer, prostate cancer, fibrosarcoma, bladder sarcoma and glioma, etc., especially lung cancer.

[0014] In a specific embodiment of the present invention, the lung cancer may include non-small cell lung cancer (eg, lung adenocarcinoma, lung squamous cell carcinoma) and small cell lung cancer.

[0015] In certain embodiments, thermophilic Deinococcus radiodurans that is anti-tumor and increases activation of killer T cells in the tumor microenvironment is combined with tumor immunotherapy techniques.

[0016] In certain embodiments, tumor immunotherapy refers to the treatment or prevention of cancer by methods including inducing, enhancing, inhibiting or otherwise altering an immune response, and specifically may include tumor immune checkpoint inhibitor therapy.

[0017] Immune checkpoints are regulatory pathways within the immune system that are involved in maintaining immune homeostasis (e.g., self-tolerance, regulating the duration and magnitude of immune responses) to minimize cellular damage due to abnormal immune responses. Immune checkpoint inhibitors inhibit immune checkpoints and may have stimulatory or inhibitory effects on immune responses.

[0018] Many immune checkpoint inhibitors are known in the art, and many treatments have been approved by regulatory agencies, including antibody treatments, while other treatments, including treatments using monoclonal antibodies or antibody fragments (such as single domain antibodies), have shown efficacy across a wide range of cancers. Immune checkpoint inhibitors generally act on the following three targets: ① T lymphocyte-associated antigen 4 (CTLA-4); ② programmed cell death protein receptor 1 (PD-1); ③ programmed cell death protein ligand 1 (PD-L1), or may also act on CD47, CD112R, etc.

[0019] In a specific embodiment of the present invention, the immune checkpoint inhibitor is any compound or biological molecule that inhibits the activity of an immune checkpoint (e.g., PD-1), which blocks the binding of PD-L1 expressed on cancer and / or immune cells to PD-1 expressed on immune cells (T cells, B cells, or NKT cells) and preferably also blocks the binding of PD-L2 expressed on cancer and / or immune cells to PD-1 expressed on immune cells.

[0020] In one embodiment, the immune checkpoint inhibitor is a PD-1 inhibitor, a PD-L1 inhibitor, or a PD-L2 inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 or anti-PD-L2 antibody. In one embodiment, the immune checkpoint inhibitor is an anti-PD-1 antibody. In one embodiment, the immune checkpoint inhibitor is an anti-PD-1 or PD-L1 antibody, optionally selected from nivolumab (MDX-1106, MDX-1106-04, ONO-4538 or BMS-936558), pembrolizumab, cemiplimab, avelumab, durvalumab, atezolizumab, spartalizumab, camrelizumab, tislelizumab, pidilizumab, pembrolizumab, or toripalimab, etc.

[0021] The present invention also provides the use of thermophilic radioresistant Deinococcus and immune checkpoint inhibitors in the preparation of drugs for anti-tumor and increasing the infiltration of cytotoxic T cells in the tumor microenvironment. The thermophilic radioresistant Deinococcus is any one of the following: live thermophilic radioresistant Deinococcus; lysate or culture of thermophilic radioresistant Deinococcus; or, attenuated, inactivated, physically treated or chemically treated thermophilic radioresistant Deinococcus, or its lysate or culture. The tumor is a lung, and / or a tumor of the esophagus, stomach, colorectum, liver, breast, prostate, bladder and nerves, in particular a lung tumor.

[0022] The activation characteristics of cytotoxic T cells in the tumor microenvironment include: increased secretion of TNF-α, IFN-γ, and GZMB by cytotoxic T cells.

[0023] The present invention also provides a therapeutic and preventive pharmaceutical composition and kit, which comprises thermophilic radioresistant Deinococcus and immune checkpoint inhibitors as active pharmaceutical ingredients. In certain embodiments, the pharmaceutical composition may also contain other microbial strains. In one aspect, the thermophilic radioresistant Deinococcus can activate killer T cells and inhibit tumor growth. In one aspect, the tumor is a solid tumor, including but not limited to solid tumors such as lung cancer, esophageal cancer, gastric cancer, colorectal cancer, melanoma, liver cancer, breast cancer, prostate cancer, fibrosarcoma, bladder sarcoma and glioma, especially lung cancer.

[0024] According to one aspect of the present invention, in the above-mentioned pharmaceutical composition, the thermophilic Deinococcus radiodurans is any one of the following: live thermophilic Deinococcus radiodurans; a lysate or culture of thermophilic Deinococcus radiodurans; or, attenuated, inactivated, physically treated or chemically treated thermophilic Deinococcus radiodurans, or a lysate or culture thereof.

[0025] According to one aspect of the present invention, the drug combination of the present invention increases the activation of killer T cells in the tumor microenvironment to achieve anti-tumor effects.

[0026] According to one aspect of the present invention, the pharmaceutical composition or kit of the present invention comprises a pharmaceutically effective dose of thermophilic radioresistant Deinococcus and an immune checkpoint inhibitor, and a pharmaceutically acceptable carrier.

[0027] Preferably, in the above-mentioned pharmaceutical composition or kit, the thermophilic radioresistant Deinococcus is any one of the following: live thermophilic radioresistant Deinococcus; a lysate or culture of thermophilic radioresistant Deinococcus; or, attenuated, inactivated, physically treated or chemically treated thermophilic radioresistant Deinococcus, or a lysate or culture thereof.

[0028] Preferably, in the above-mentioned pharmaceutical composition, the thermophilic radioresistant Deinococcus can be in any one or more pharmaceutically feasible dosage forms, including but not limited to tablets, capsules, oral solutions or lyophilized powders.

[0029] Preferably, in the above-mentioned pharmaceutical composition, the pharmaceutically acceptable carrier is a mixture of one or more of skim milk, lactose, glucose, sucrose, sorbitol, mannose, trehalose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil.

[0030] According to one aspect of the present invention, the thermophilic radioresistant Deinococcus combined with immune checkpoint inhibitors achieves anti-tumor function by increasing the activation of cytotoxic T cells in the tumor microenvironment.

[0031] The present invention uses lung cancer organoids as a research model, and analyzes, detects and identifies the function of thermophilic radioresistant Deinococcus in lung cancer immunotherapy response and tolerance organoid models. The present invention has experimentally demonstrated that thermophilic radioresistant Deinococcus combined with immune checkpoint inhibitors can significantly increase the activation of killer T cells in the tumor microenvironment and effectively inhibit tumor growth, indicating that the combination of thermophilic radioresistant Deinococcus and immune checkpoint inhibitors has important development and application value in clinical tumor treatment.

[0032] The thermophilic radioresistant Deinococcus referred to in the present invention includes but is not limited to any one of the following: live thermophilic radioresistant Deinococcus; a lysate or culture of thermophilic radioresistant Deinococcus; or, attenuated, inactivated, physically treated or chemically treated thermophilic radioresistant Deinococcus, or a lysate or culture thereof.

[0033] The tumor is a solid tumor, such as but not limited to lung cancer, esophageal cancer, gastric cancer, colorectal cancer, melanoma, liver cancer, breast cancer, prostate cancer, fibrosarcoma, bladder sarcoma and glioma. In certain embodiments, the tumor includes but is not limited to: liver cancer and / or breast cancer.

[0034] The present invention also provides an anti-tumor pharmaceutical composition comprising a pharmaceutically effective dose of thermophilic radioresistant Deinococcus. The so-called "pharmaceutically effective dose" has a range of 10 6 ~10 10 CFU, preferably 10 9 CFU.

[0035] The pharmaceutical composition includes, but is not limited to, tablets, capsules, oral solutions or freeze-dried powders. The pharmaceutically acceptable carrier includes, but is not limited to, one or more of skim milk, lactose, glucose, sucrose, sorbitol, gum arabic, mannose, starch, trehalose, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil.

[0036] In a specific embodiment of the present invention, the culture of thermophilic Deinococcus radiodurans refers to a bacterial population or growth product in a liquid or solid culture medium after artificial inoculation and culture of thermophilic Deinococcus radiodurans.

[0037] In a specific embodiment of the invention, the chemotherapeutic agent is selected from any one or more of the following: lenalidomide (REVLIMID), proteasome inhibitors (e.g., bortezomib (VELCADE) and PS342), plant-derived (vincristine, vinblastine, etoposide, irinotecan, nogitecan, paclitaxel, docetaxel), borotaxanes (including docetaxel and paclitaxel), periwinkle (e.g., vinorelbine or vinblastine), platinum compounds (e.g., carboplatin, cisplatin or nedaplatin), aromatase inhibitors (e.g., letrozole, anastrozole, or exemestane), antiestrogens (e.g., fulvestrant or tamoxifen), etoposide, thiotepa, alkylating agents (cyclophosphamide, ifosfamide), methotrexate, liposomal doxorubicin, pegylated liposomal doxorubicin, capecitabine, gemcitabine, vinorelbine, messalin, anticancer antibiotics (bleomycin, pembryonic acid, mitomycin C, doxorubicin, epirubicin, pirarubicin), vincristine, irinotecan, COX-2 inhibitors (such as celecoxib) or steroids (such as dexamethasone and prednisone), metabolic antagonists (5-fluorouracil, UFT (tegafur uracil), doxifluridine and TS-1 (also abbreviated as S-1) (tegafur, gimeracil and octacil potassium), cytarabine).

[0038] Specifically, the present invention provides the following technical solutions:

[0039] 1. A pharmaceutical composition or kit comprising thermophilic radioresistant Deinococcus geothermalis and an immune checkpoint inhibitor.

[0040] 2. The pharmaceutical composition or kit according to item 1, wherein the pharmaceutical composition or kit further comprises a pharmaceutically acceptable carrier, or the kit further comprises a chemotherapeutic agent.

[0041] 3. The pharmaceutical composition or kit according to item 1, wherein the thermophilic Deinococcus radioresistance is any one or more of the following: live thermophilic Deinococcus radioresistance bacteria; a lysate or culture of thermophilic Deinococcus radioresistance bacteria; or thermophilic Deinococcus radioresistance bacteria that has been attenuated, inactivated, physically treated or chemically treated, or a lysate or culture thereof; optionally, the content of the thermophilic Deinococcus radioresistance bacteria is 10 6 ~10 10 CFU, preferably 10 9 CFU.

[0042] 4. The pharmaceutical composition or kit according to item 1, wherein the immune checkpoint is selected from one or more of T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein receptor 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1), CD47, CD112R, and preferably, the immune checkpoint inhibitor is a compound or biological macromolecule (such as an antibody) that inhibits the immune checkpoint, such as an antibody targeting the immune checkpoint, such as nivolumab (MDX-1106, MDX-1106-04, ONO-4538 or BMS-93 6558), pembrolizumab, cemiplimab, avelumab, durvalumab, atezolizumab, spartalizumab, camrelizumab, tislelizumab, pidilizumab, toripalimab, pembrolizumab and one or more of tislelizumab.

[0043] 5. The pharmaceutical composition or kit according to item 1, wherein the thermophilic radioresistant Deinococcus is in the form of tablets, capsules, oral solutions, injections or lyophilized powders.

[0044] 6. Use of thermophilic radioresistant Deinococcus and immune checkpoint inhibitors in the preparation of a pharmaceutical composition or kit for treating tumors.

[0045] 7. The use according to item 6, wherein the thermophilic Deinococcus radiodurans is any one or more of the following: live thermophilic Deinococcus radiodurans; a lysate or culture of thermophilic Deinococcus radiodurans; or, attenuated, inactivated, physically treated or chemically treated thermophilic Deinococcus radiodurans, or a lysate or culture thereof.

[0046] 8. The use according to item 6, wherein the immune checkpoint is selected from one or more of T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein receptor 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1), CD47, CD112R, and preferably, the immune checkpoint inhibitor is a compound or biological macromolecule (such as an antibody) that inhibits the immune checkpoint, such as an antibody targeting the immune checkpoint, such as nivolumab (MDX-1106, MDX-1106-04, ONO-4538 or BMS-936558 ), pembrolizumab, cemiplimab, avelumab, durvalumab, atezolizumab, spartalizumab, camrelizumab, tislelizumab, pidilizumab, toripalimab, pembrolizumab and one or more of tislelizumab.

[0047] 9. The use according to item 6, wherein the tumor is a solid tumor, including but not limited to lung cancer (such as lung adenocarcinoma, lung squamous cell carcinoma), esophageal cancer, gastric cancer, colorectal cancer, melanoma, liver cancer, breast cancer, prostate cancer, fibrosarcoma, bladder sarcoma or glioma.

[0048] 10. The use according to item 6, wherein the thermophilic Deinococcus radiodurans and the immune checkpoint inhibitor are in a form suitable for simultaneous, sequential or separate administration; optionally, the thermophilic Deinococcus radiodurans and the immune checkpoint inhibitor are in a form suitable for administration by the same or different administration methods. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 Schematic diagram of the experimental process for testing the effect of live thermophilic Deinococcus radioresistant bacteria combined with PD-1 antibody treatment on increasing the activation of cytotoxic T cells in the tumor microenvironment in the lung cancer organoid model. The time of administration of bacteria or organoids is expressed in days (day, d).

[0050] Figure 2 Schematic diagram of the experimental process for testing the effect of thermophilic radioresistant Deinococcus radiodurans supernatant or bacterial lysate combined with PD-1 antibody treatment on increasing the activation of cytotoxic T cells in the tumor microenvironment in the lung cancer organoid model. The time of administration of bacteria or organoids is expressed in days (day, d).

[0051] Figure 3This is a diagram showing the expression of TNF-α in each group measured by enzyme-linked immunosorbent assay (ELISA) after the addition of live thermophilic radioresistant Deinococcus aureus combined with anti-PD-1 antibody treatment (such as pembrolizumab or tislelizumab) to the lung cancer organoid model.

[0052] Figure 4 This is a diagram showing the expression of IFN-γ in each group measured by enzyme-linked immunosorbent assay (ELISA) after the addition of live thermophilic radioresistant Deinococcus aureus combined with anti-PD-1 antibody treatment (such as pembrolizumab or tislelizumab) to the lung cancer organoid model.

[0053] Figure 5 After adding live thermophilic radioresistant Deinococcus radiatus bacteria combined with anti-PD-1 antibody treatment (such as pembrolizumab or tislelizumab) to the lung cancer organoid model, the number of viable tumor cells in each group was determined using Incucyte S3.

[0054] Figure 6 This is a diagram showing the expression of TNF-α in each group measured by enzyme-linked immunosorbent assay (ELISA) after adding thermophilic radioresistant Deinococcus supernatant or bacterial precipitate lysate combined with PD-1 antibody treatment (such as tislelizumab) to the lung cancer organoid model.

[0055] Figure 7 This is a diagram showing the expression of IFN-γ in each group measured by enzyme-linked immunosorbent assay (ELISA) after adding thermophilic radioresistant Deinococcus radiodurans supernatant or bacterial precipitate lysate combined with PD-1 antibody treatment (such as tislelizumab) to the lung cancer organoid model.

[0056] Figure 8 After adding the supernatant or bacterial pellet lysate of thermophilic Deinococcus radiodurans combined with PD-1 antibody treatment (such as tislelizumab) to the lung cancer organoid model, the number of viable tumor cells in each group was determined using Incucyte S3.

[0057] Fig. 9 This is the ratio of GZMB and CD3 positive cells after adding thermophilic radioresistant Deinococcus supernatant or bacterial precipitate lysate combined with anti-PD-1 antibody treatment (tislelizumab) to the lung cancer organoid model. DETAILED DESCRIPTION

[0058] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.

[0059] The methods used in the following examples are conventional methods unless otherwise specified, and the reagents used are commercially available reagents unless otherwise specified.

[0060] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical scheme of the present invention is now described in detail below in conjunction with specific embodiments and drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. Unless otherwise specifically defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the relevant art. The method operations not specifically noted in the embodiments are performed according to the conventional operations of the prior art in the relevant field or the operations recommended by the manufacturer's instructions.

[0061] Strain source:

[0062] Thermophilic radioresistant Deinococcus geothermalis (Deinococcus geothermalis) was obtained from CCUG, and the strain deposit number is CCUG 73331.

[0063] Example 1: Cultivation of thermophilic Deinococcus radioresistant

[0064] Cultivation method:

[0065] Step 1: Take a freeze-dried thermophilic radioresistant Deinococcus geothermalis strain and add 1 mL of nutrient broth (BD Difco TM NB medium (commercially available from Fisher Scientific) was dissolved, 200 μl was streaked on a nutrient broth agar plate, and cultured in an incubator at 37° C. under aerobic conditions for 48 hours;

[0066] Step 2: Pick a single clone and dissolve it in 5 ml of nutrient broth medium, and culture it at 37°C under aerobic conditions for 48 hours;

[0067] Step 3: Take 100 ml of nutrient broth medium, inoculate the bacteria cultured in step 2 at 1% (v / v), and culture at 37°C under aerobic conditions for 48 hours;

[0068] Step 4: Collect the bacterial solution and centrifuge at 3000 rpm for 10 minutes. Wash twice with saline and then re-dissolve the bacterial precipitate for later use and count the viable bacteria.

[0069] Example 2: Experiment on the ability of thermophilic radioresistant Deinococcus to significantly increase the activation of cytotoxic T cells in the tumor microenvironment and effectively inhibit tumor growth

[0070] Figure 1 and Figure 2 Schematic diagram of the experimental process of administering thermophilic radioresistant Deinococcus and PD-1 antibodies.

[0071] 1. Cultivation methods

[0072] The method for culturing thermophilic radiation-resistant Deinococcus bacteria is the same as that in the above-mentioned Example 1.

[0073] 2. Sample preparation of thermophilic Deinococcus radiodurans

[0074] 1) Preparation of live thermophilic Deinococcus radiodurans bacteria

[0075] Step 1: Take a freeze-dried thermophilic radioresistant Deinococcus geothermalis strain, add 1 mL of nutrient broth medium (NB medium) to dissolve it, take 200 μl and streak it on a nutrient broth agar plate, and culture it in an incubator at 37° C. under aerobic conditions for 48 hours;

[0076] Step 2: Pick a single clone and dissolve it in 5 ml of nutrient broth medium, and culture it at 37°C under aerobic conditions for 48 hours;

[0077] Step 3: Take 100 ml of nutrient broth medium, inoculate the bacteria at 1% (v / v), and culture at 37°C under aerobic conditions for 48 hours;

[0078] Step 4: Collect the bacterial solution and centrifuge at 3000 rpm for 10 minutes. Wash twice with saline and then re-dissolve the bacterial precipitate for later use and count the viable bacteria.

[0079] 2) Preparation of inactivated bacterial lysate of thermophilic Deinococcus radioresistant bacteria

[0080] After counting the viable bacteria, the thermophilic radioresistant Deinococcus precipitate was heated in a 75°C water bath for 30 minutes to obtain inactivated bacteria. It was frozen in liquid nitrogen for 30 minutes and thawed at 37°C for 30 minutes, and this was repeated three times. It was then treated by ultrasonic disruption, with ultrasonication for 2 seconds, and then stopped for 5 seconds, for a total of 10 minutes, to obtain a thermophilic radioresistant Deinococcus lysate.

[0081] 3) Preparation of the culture supernatant of thermophilic radioresistant Deinococcus radiatus

[0082] The culture solution of the thermophilic Deinococcus radioresistant was taken after the live bacteria were counted, and centrifuged at 3000 rpm for 10 minutes. The supernatant after centrifugation was filtered through a 0.22 μm microporous filter membrane and collected as the thermophilic Deinococcus radioresistant culture supernatant.

[0083] 3. Experiment on enhancing the efficacy of tumor immunotherapy by combining thermophilic radioresistant Deinococcus with PD-1 antibody

[0084] Source of tumor tissue samples: The tumor samples used in this experiment were from Beijing Cancer Hospital. All operations have been reviewed by the Ethics Committee of Beijing Cancer Hospital, and the patients and their families have signed informed consent.

[0085] Lung cancer organoid drug sensitivity test: Based on the in vitro culture method of primary tumors from patients, the primary and recurrent resistant tissues of bronchoscopic biopsies of lung cancer patients were cut into small pieces (after washing with PBS) and digested in PBS / EDTA (1mM) containing collagenase I, II and IV (200U / mL) at 37°C for 1 hour. The digest was collected every 15 minutes to promote cell release. The dissociated cells were collected using a 40μm filter, centrifuged (300g / min) for 10 minutes, and the cell clumps were resuspended in organoid growth medium (OrganoPro TM Organoid culture medium kit, commercially available from Ketu Medical Corporation) and cells (10 5 Pieces / cm 2 ) were inoculated in low-adsorption culture dishes. The cells were cultured in an incubator at 37°C and 5% CO2 for 12 days, and the culture medium was renewed every 2-3 days to establish an in vitro tumor immunotherapy drug sensitivity detection model. Then, the D. geothermalis infection and in vitro co-culture of tumor organoids were grouped: for the combined treatment experimental group (i.e., PD-1 antibody + Dg bacteria, PD-1 antibody + Dg bacterial lysate, or PD-1 antibody + Dg bacterial supernatant), on the 12th day of tumor organoid culture, live thermophilic radioresistant Deinococcus bacteria, supernatant of thermophilic radioresistant Deinococcus bacteria, or bacterial precipitate lysate were added to the tumor organoids for infection. After 3 days of infection (i.e., day 15), PD-1 inhibitors were added for 3 days of treatment. For the control group, the same amount of PBS was added on day 12 instead of bacterial treatment, and the same amount of saline was added on day 15 instead of PD-1 antibody treatment. For the "PD-1 antibody" group, the same amount of PBS was added on the 12th day instead of the bacteria treatment, and the PD-1 antibody treatment was added on the 15th day; for the "Dg bacteria", "Dg bacteria supernatant", and "Dg bacterial lysate" groups, bacteria (live thermophilic radioresistant Deinococcus, supernatant of thermophilic radioresistant Deinococcus, or bacterial precipitate lysate, respectively) were added on the 12th day, and the same amount of normal saline was added on the 15th day instead of the PD-1 antibody treatment.

[0086] On the 15th day and the 18th day, respectively, enzyme-linked immunosorbent assay (ELISA) was used to measure the expression of TNF-α (which used a TNF-α ELISA kit, which is commercially available and purchased from R&D) and IFN-γ (which used an IFN-γ ELISA kit, which is commercially available and purchased from R&D) and on the 18th day, Incucyte S3 (IncuCyte Soft software, EssenBioScience) was used to measure the cell activity of each group; at the same time, immunofluorescence staining experiments were used to detect the expression of GZMB and CD3 (the GZMB antibody and CD3 antibody used were commercially available and purchased from Abcam). GZMB is an important T cell killer molecule, and CD3 is a T cell antigen recognition receptor. The activation degree of killer T cells can be detected by calculating the ratio of GZMB and CD3 positive cells.

[0087] Result analysis:

[0088] Figure 1 Schematic diagram of the experimental process for testing the anti-tumor effect of live thermophilic radioresistant Deinococcus combined with immune checkpoint inhibitors in a lung cancer organoid model and increasing the activation of cytotoxic T cells in the tumor microenvironment. Figure 2 Schematic diagram of the experimental process for detecting the anti-tumor effect of thermophilic radioresistant Deinococcus supernatant or thermophilic radioresistant Deinococcus precipitate lysate combined with immune checkpoint inhibitors and increasing the activation of cytotoxic T cells in the tumor microenvironment in the lung cancer organoid model. Figure 3 , Figure 4 , Figure 6 , Figure 7 The live thermophilic Deinococcus radioresistance, the supernatant of thermophilic Deinococcus radioresistance, or the precipitate lysate of thermophilic Deinococcus radioresistance combined with PD-1 antibody were added to the lung cancer organoid model, and the TNF-α( Figure 3 , Figure 6 ), IFN-γ( Figure 4 , Figure 7 )’s expression. Figure 5 , Figure 8 Live thermophilic Deinococcus radiodurans, or thermophilic Deinococcus radiodurans supernatant or thermophilic Deinococcus radiodurans precipitate lysate combined with anti-PD-1 antibody were added to the lung cancer organoid model, and the number of viable cells in each group was determined using Incucyte S3 software. Fig. 9 After adding thermophilic radioresistant Deinococcus radiodurans supernatant or thermophilic radioresistant Deinococcus radiodurans precipitate lysate combined with PD-1 antibody treatment to the lung cancer organoid model, the degree of activation of cytotoxic T cells was detected by calculating the ratio of GZMB and CD3 positive cells.

[0089] The results showed that Figure 3 , Figure 6 In the lung cancer organoid model, the addition of live thermophilic radioresistant Deinococcus or thermophilic radioresistant Deinococcus somatic lysate in vitro increased TNF-α induced by PD-1 inhibitors by about 100 times. Figure 4 , Figure 7 The experimental results found that the addition of live thermophilic radioresistant Deinococcus or thermophilic radioresistant Deinococcus lysate in vitro in the lung cancer organoid model can increase the IFN-γ induced by PD-1 inhibitors by about 50-60 times, and these increases are statistically significant. Figure 5 , Figure 8 The results of the Incucyte S3 live cell assay experiment showed that in the groups where live thermophilic radioresistant Deinococcus aureus or thermophilic radioresistant Deinococcus aureus lysate combined with PD-1 antibody were added, the number of live tumor cells decreased by about 20-30%, and the reduction was statistically significant. Fig. 9 The results of immunofluorescence staining experiments clearly showed that after treatment with thermophilic radioresistant Deinococcus lysate combined with PD-1 antibody, the proportion of GZMB-positive cells in lung cancer organoids increased significantly, indicating that the activation of cytotoxic T cells was increased. These experimental results show that the use of live thermophilic radioresistant Deinococcus lysate or thermophilic radioresistant Deinococcus lysate combined with PD-1 antibody treatment can increase the activation of cytotoxic T cells in the tumor microenvironment and significantly inhibit tumor growth.

[0090] In the statistical analysis graphs of the above results, * indicates student t-test p<0.05, and *** indicates student t-test p<0.001. p<0.05 is considered statistically significant. Each experiment was repeated at least 3 times.

[0091] In summary, live thermophilic Deinococcus radiodurans or thermophilic Deinococcus radiodurans lysate combined with PD-1 antibody treatment can increase the secretion of TNF-α, IFN-γ, and GZMB in cytotoxic T cells ( Figure 3 , Figure 4 , Figure 6 , Figure 7 , Fig. 9 ).also, Figure 5 , Figure 8 The experimental results show that live thermophilic radioresistant Deinococcus or thermophilic radioresistant Deinococcus somatic lysate combined with PD-1 antibody treatment can significantly reduce the number of tumor cells, promote the tumor-killing function of immunotherapy, and has a good effect on the prevention and treatment of tumors such as lung cancer.

[0092] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A pharmaceutical composition or kit comprising thermophilic radioresistant Deinococcus geothermalis and an immune checkpoint inhibitor.

2. The pharmaceutical composition or kit according to claim 1, wherein The pharmaceutical composition or kit further comprises a pharmaceutically acceptable carrier, or the kit further comprises a chemotherapeutic agent.

3. The pharmaceutical composition or kit according to claim 1, wherein The thermophilic Deinococcus radioresistance is any one or more of the following: live thermophilic Deinococcus radioresistance bacteria; lysate or culture of thermophilic Deinococcus radioresistance bacteria; or thermophilic Deinococcus radioresistance bacteria that have been attenuated, inactivated, physically treated or chemically treated, or lysate or culture thereof; optionally, the content of the thermophilic Deinococcus radioresistance bacteria is 10 6 ~10 10 CFU, preferably 10 9 CFU.

4. The pharmaceutical composition or kit according to claim 1, wherein The immune checkpoint is selected from one or more of T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein receptor 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1), CD47, CD112R. Preferably, the immune checkpoint inhibitor is a compound or biological macromolecule (such as an antibody) that inhibits the immune checkpoint, such as an antibody targeting the immune checkpoint, such as nivolumab (MDX-1106, MDX-1106-04, ONO-4538 or BMS-936558), pembrolizumab, sirolimus, or avilanzine. One or more of cemiplimab, avelumab, durvalumab, atezolizumab, spartalizumab, camrelizumab, tislelizumab, pidilizumab, toripalimab, pembrolizumab and tislelizumab.

5. The pharmaceutical composition or kit according to claim 1, wherein The thermophilic radioresistant Deinococcus is in the form of tablets, capsules, oral liquid, injection or lyophilized powder.

6. Use of thermophilic radioresistant Deinococcus and immune checkpoint inhibitors in the preparation of a pharmaceutical composition or kit for treating tumors.

7. The use according to claim 6, wherein The thermophilic radioresistant Deinococcus is any one or more of the following: live thermophilic radioresistant Deinococcus; a lysate or culture of thermophilic radioresistant Deinococcus; or attenuated, inactivated, physically treated or chemically treated thermophilic radioresistant Deinococcus, or a lysate or culture thereof.

8. The use according to claim 6, wherein The immune checkpoint is selected from one or more of T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein receptor 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1), CD47, CD112R. Preferably, the immune checkpoint inhibitor is a compound or biological macromolecule (such as an antibody) that inhibits the immune checkpoint, such as an antibody targeting the immune checkpoint, such as nivolumab (MDX-1106, MDX-1106-04, ONO-4538 or BMS-936558), pembrolizumab, sirolimus, or avilanzine. One or more of cemiplimab, avelumab, durvalumab, atezolizumab, spartalizumab, camrelizumab, tislelizumab, pidilizumab, toripalimab, pembrolizumab and tislelizumab.

9. The use according to claim 6, wherein The tumor is a solid tumor, including but not limited to lung cancer (such as lung adenocarcinoma, lung squamous cell carcinoma), esophageal cancer, gastric cancer, colorectal cancer, melanoma, liver cancer, breast cancer, prostate cancer, fibrosarcoma, bladder sarcoma or glioma.

10. The use according to claim 6, wherein: The thermophilic Deinococcus radiodurans and the immune checkpoint inhibitor are in a form suitable for simultaneous, sequential or separate administration; optionally, the thermophilic Deinococcus radiodurans and the immune checkpoint inhibitor are in a form suitable for administration by the same or different administration methods.